Pharma BD Deal Intelligence
A small, profitable bolt-on that Inverness folded in and then shut down within three years — the BioStar OIA line and its Colorado plant were exited in 2008 with a $10.6M impairment/restructuring charge, even as parent Inverness (later Alere) grew via dozens of other acquisitions before its own scandal-driven sale to Abbott in 2017.
Full analysis, sources & comparables →Covington Associates advised Inverness Medical Innovations on its acquisition of Thermo Electron's BioStar division, an advisor announcement framing the…
LabMedica framed the BioStar deal as part of an Inverness roll-up of POC diagnostics — paired with the ~$11.8M Innogenetics Diagnostica purchase — building…
Deals roundup notes Inverness closes its BioStar buy, neutral trade-press confirmation that the rapid-diagnostics acquisition completed as announced.
Source summaries from our enrichment pipeline; follow links for originals.
All 6 sources with sentiment breakdown →
Inverness acquires Thermo BioStar from Thermo Electron for ~$52.5M; rapid diagnostics for infectious disease.
A small, profitable bolt-on that Inverness folded in and then shut down within three years — the BioStar OIA line and its Colorado plant were exited in 2008 with a $10.6M impairment/restructuring charge, even as parent Inverness (later Alere) grew via dozens of other acquisitions before its own scandal-driven sale to Abbott in 2017.
Assessment window: 15yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Inverness Medical Innovations Inc. / Thermo BioStar, Inc. (this deal) | 2005 | $52M | 31 |
| Inverness Medical Innovations Inc. / Abbott Laboratories Rapid Diagnostics (pregnancy / drug-of-abuse lines) | 2003 | $92M | 71 |
| Inverness Medical Innovations Inc. / Innogenetics Diagnostica y Terapeutica S.A. (IDT) | 2005 | $19M | 45 |
| Inverness Medical Innovations Inc. / Ischemia Technologies Inc. | 2004 | $22M | 33 |
| Inverness Medical Innovations Inc. / Binax Inc. | 2004 | — | — |
| AstraZeneca PLC / KuDOS Pharmaceuticals Limited | 2005 | $210M | 98 |
| Yamanouchi Pharmaceutical / Fujisawa Pharmaceutical Co. Ltd. | 2005 | — | 92 |